Why Peptide Dosing Is Different From Everything Else
When your doctor prescribes ibuprofen, the dose is printed on the box. It went through Phase I, II, and III clinical trials. The FDA reviewed the safety data. A pharmacist double-checks the math. None of that exists for most research peptides.
The majority of peptides in the Athena compound library have never been through human dose-finding trials. BPC-157 has 544+ preclinical articles and exactly three small human studies — none of which established a standardized therapeutic dose. TB-500 has zero human clinical trials. The "doses" circulating online for these compounds are extrapolated from rodent studies, copied from grey-market vendor labels, or shared anecdotally in forums and Discord servers.
That is not dosing. That is guessing.
The Four-Conversion Problem
Peptide dosing involves a chain of unit conversions that doesn't exist in regular medicine. Every step is a chance to misplace a decimal or confuse a unit:
Step 2: Target dose is in micrograms (mcg) — 1 mg = 1,000 mcg
Step 3: Reconstitute with bacteriostatic water in milliliters (mL)
Step 4: Draw on insulin syringe in units — 100 units = 1 mL
Example: 5 mg vial + 2 mL BAC water = 2,500 mcg/mL
Target dose: 250 mcg → draw 0.1 mL = 10 units on U-100 syringe
If you add 1 mL of water instead of 2 mL, the concentration doubles. Your 10-unit draw is now 500 mcg instead of 250 mcg. You just took double your intended dose because you misread a syringe. There's no pharmacist catching that at 2 AM.
For GLP-1 compounds like semaglutide, the math gets even more involved because dosing requires a slow titration schedule over weeks. Starting at the full dose instead of the starting dose is one of the most common causes of severe nausea, vomiting, and in extreme cases, pancreatitis (Marcus, 2026).
What Grey-Market Testing Actually Finds
Even if your math is perfect, the label might not be. A 2026 investigation by WBUR found that grey-market peptide vendors routinely mislabel vial contents. One source described the problem directly: a vial labeled 5 mg might contain 15 mg (Marcus, 2026). If you calculate your dose based on 5 mg and the vial actually contains 15 mg, every injection is three times what you intended.
This is not theoretical. The same investigation documented an individual who took an excessive dose of retatrutide (a GLP-1 triple agonist) for a bodybuilding competition. The result was acute necrotizing pancreatitis — his pancreas failed.
Route of Administration Changes the Dose Entirely
A "dose" without a route is meaningless. Oral BPC-157 has completely different bioavailability than subcutaneous injection, which is different from IV infusion, which is different from intra-articular injection. The same number of micrograms delivered by different routes produces entirely different blood concentrations. Published studies specify the route for exactly this reason.
Rodent Doses Don't Scale Linearly to Humans
A dose that works in a 300-gram rat does not scale to a 75-kilogram human by simply multiplying body weight. Allometric scaling requires accounting for metabolic rate, body surface area, clearance rates, and species-specific pharmacokinetics. The FDA has published specific guidance on interspecies dose conversion for exactly this reason (FDA, 2005). Simply multiplying the rat dose by 250 produces a number, not a dose.
Dosages Reported in Published Studies
The table below reflects dosages as reported in peer-reviewed literature and clinical records. These are not recommendations. They are records of what researchers used in specific, controlled study contexts with institutional oversight.
| Compound | Study | Dose Reported | Route | Source |
|---|---|---|---|---|
| BPC-157 | Knee pain pilot (n=16) | 2cc of 2,000 mcg/mL solution | Intra-articular | Case series, 2021 |
| BPC-157 | Interstitial cystitis (n=12) | 10 mg (single injection) | Intravesical | Lee et al., 2024 |
| BPC-157 | IV safety pilot (n=2) | 10 mg Day 1, 20 mg Day 2 | IV infusion | Lee & Burgess, 2025 |
| GHK-Cu | Post-laser recovery | 0.05% gel formulation | Topical | Yamada et al., 2025 |
| GHK-Cu | Facial aging (n=71, 12 wks) | Cream formulation | Topical | Pickart & Margolina, 2018 |
| Retatrutide | Phase II T2D (Lancet) | 0.5 – 12 mg weekly | SC injection | Jastreboff et al., 2023 |
| Semaglutide | FDA-approved (Wegovy) | 0.25 – 2.4 mg weekly | SC injection | FDA prescribing info |
| NMN (NAD+) | Human RCT (12 wks) | 250 mg daily | Oral | GeroScience, 2024 |
| Thymosin β4 | MI pilot (n=18) | Autologous EPC pre-treatment | IV | Zhu et al., 2016 |
| TB-500 | No human trials exist | N/A | N/A | — |
Notice the pattern. Actual study dosages are specific, controlled, titrated, and reported with route, duration, and context. They look nothing like "take 250 mcg twice daily" — the kind of unsourced instruction that circulates on forums.
Also notice the gaps. BPC-157 has been used at vastly different doses across its three human studies — because no dose-finding trial has ever established what the "right" dose is for any indication. TB-500 has a blank row because there is literally nothing to report.
Visual: Semaglutide Titration Schedule (FDA-Approved)
Semaglutide is one of the few peptides with a fully validated, FDA-approved dosing protocol. This is what evidence-based titration actually looks like — contrast this with the absence of any equivalent data for most research peptides.
| Week | Dose | Purpose | Avg Weight Loss | Syringe Draw* |
|---|---|---|---|---|
| 1–4 | 0.25 mg | Starter dose — acclimation only, not therapeutic | ~1–2% | 5 units (at 5 mg/2 mL) |
| 5–8 | 0.5 mg | First therapeutic dose — appetite suppression begins | ~4–5% | 10 units |
| 9–12 | 1.0 mg | Increased efficacy — consistent weight loss | ~7–8% | 20 units |
| 13–16 | 1.7 mg | Strong appetite control — many maintain here | ~10–12% | 34 units |
| 17+ | 2.4 mg | FDA maximum maintenance dose (Wegovy) | ~15–17% | 48 units |
*Syringe units assume compounded semaglutide at 5 mg/2 mL concentration using U-100 insulin syringe. Pre-filled pens (Ozempic, Wegovy) use manufacturer-set doses and do not require manual calculation. Weight loss percentages from STEP 1 and STEP 3 clinical trials (68 weeks). Individual results vary. This is not a recommendation — it is a record of the FDA-approved protocol.
Visual: Reconstitution Math — What the Numbers Actually Mean
This chart shows how the same vial produces completely different doses depending on how much water you add. One variable changes everything.
| Vial Size | BAC Water Added | Concentration | 250 mcg Draw | 500 mcg Draw | Doses per Vial (at 250 mcg) |
|---|---|---|---|---|---|
| 5 mg | 1 mL | 5,000 mcg/mL | 5 units | 10 units | 20 doses |
| 5 mg | 2 mL | 2,500 mcg/mL | 10 units | 20 units | 20 doses |
| 5 mg | 3 mL | 1,667 mcg/mL | 15 units | 30 units | 20 doses |
| 10 mg | 2 mL | 5,000 mcg/mL | 5 units | 10 units | 40 doses |
| 10 mg | 3 mL | 3,333 mcg/mL | 7.5 units | 15 units | 40 doses |
All calculations use U-100 insulin syringe (100 units = 1 mL). Total doses per vial remain the same regardless of water volume — only the draw volume changes. This table is for educational math reference only and does not constitute dosing guidance. Consult a qualified physician.
Visual: BPC-157 — What Was Actually Used in Human Studies
Three human studies. Three completely different doses, routes, and concentrations. This is what happens when no dose-finding trial has ever been completed.
| Study | Year | Subjects | Dose | Route | Frequency | Outcome |
|---|---|---|---|---|---|---|
| Knee Pain | 2021 | 16 patients | 2cc of 2,000 mcg/mL (= 4,000 mcg total) | Intra-articular injection | Single injection | 87.5% reported relief at 6–12 months. No control group. |
| Interstitial Cystitis | 2024 | 12 patients | 10 mg (= 10,000 mcg) | Intravesical (bladder) injection | Single injection | 80–100% symptom resolution. No control group. |
| IV Safety | 2025 | 2 adults | 10 mg Day 1, 20 mg Day 2 | IV infusion over 1 hour | 2 days | No adverse events. Plasma cleared within 24 hours. |
Note: The knee pain study used 4,000 mcg in a single injection. The IV safety study used 10,000–20,000 mcg (10–20 mg). The commonly cited "250 mcg twice daily" protocol that circulates online does not appear in any published human study. These are records of published data, not dosing recommendations.
What "Dosing" Means for Compounds Without Human Data
For FDA-approved peptides like semaglutide, dosing follows a validated titration protocol refined through Phase I–III trials involving thousands of patients. The starting dose, escalation schedule, maximum dose, and adjustment criteria are all evidence-based.
For unapproved research peptides, none of that infrastructure exists. There is no starting dose. There is no maximum dose. There is no titration schedule. There are no dose-adjustment guidelines for renal impairment, hepatic impairment, drug interactions, or age.
When someone online tells you to "take 250 mcg of BPC-157 twice daily," they are not citing a clinical protocol. They are citing a convention that emerged from anecdotal reports and vendor marketing — then got repeated so many times it started sounding like science. It isn't.
The dose makes the poison. But for most research peptides, no one has determined where the poison starts — because the studies haven't been done.
Paracelsus (1493–1541), adapted for peptide contextThe Bottom Line
Peptide dosing is not a detail you figure out from a Reddit thread. It requires understanding unit conversions (mg → mcg → mL → syringe units), route-specific bioavailability, reconstitution math, storage stability, and — most critically — whether any human dosing data even exists for the compound in question.
For most research peptides, it doesn't. That's not a reason to avoid learning. It's the reason learning matters more.
References (APA 7th Edition)
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., ... & Hartman, M. L. (2023). Triple-hormone-receptor agonist retatrutide for obesity — a Phase 2 trial. The New England Journal of Medicine, 389(6), 514–526.
Lee, Y. K., & Burgess, L. (2025). Intravenous BPC-157 safety and pharmacokinetics in healthy adults: A pilot study. Alternative Therapies in Health and Medicine.
Lee, Y. K., Choi, H. Y., & Kim, J. H. (2024). Intravesical BPC-157 injection for interstitial cystitis: A preliminary report. Alternative Therapies in Health and Medicine, 30(6), 42–46.
Marcus, E. (2026, March 24). People are buying unregulated, injectable peptides from Chinese factories. Are they safe? WBUR Here & Now.
Pickart, L., & Margolina, A. (2018). Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences, 19(7), 1987.
U.S. Food and Drug Administration. (2005). Guidance for industry: Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. FDA.
Vasireddi, N., et al. (2025). Emerging use of BPC-157 in orthopaedic sports medicine: A systematic review. American Journal of Sports Medicine.
Zhu, J., et al. (2016). Safety and efficacy of autologous thymosin β4 pre-treated endothelial progenitor cell transplantation. Cytotherapy, 18(8), 1037–1042.